107 related articles for article (PubMed ID: 28699073)
1. Sub-therapeutic darunavir concentration and garlic consumption; a «Mediterranean» drug-food interaction, about 2 cases.
Cloarec N; Solas C; Ladaique A; Tamalet C; Zaegel-Faucher O; Bregigeon S; Canet B; Cano CE; Poizot-Martin I
Eur J Clin Pharmacol; 2017 Oct; 73(10):1331-1333. PubMed ID: 28699073
[No Abstract] [Full Text] [Related]
2. Risk factors contributing to a low darunavir plasma concentration.
Daskapan A; Stienstra Y; Kosterink JGW; Bierman WFW; van der Werf TS; Touw DJ; Alffenaar JC
Br J Clin Pharmacol; 2018 Mar; 84(3):456-461. PubMed ID: 29077230
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.
Kakuda TN; Sekar V; Lavreys L; De Paepe E; Stevens T; Vanstockem M; Vangeneugden T; Hoetelmans RM
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):346-52. PubMed ID: 27129006
[TBL] [Abstract][Full Text] [Related]
4. Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
[TBL] [Abstract][Full Text] [Related]
5. Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions.
Berginc K; Kristl A
J Med Food; 2011; 14(1-2):135-9. PubMed ID: 21138349
[TBL] [Abstract][Full Text] [Related]
6. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
[TBL] [Abstract][Full Text] [Related]
7. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
[TBL] [Abstract][Full Text] [Related]
8. Garlic supplements found to lower saquinavir levels.
TreatmentUpdate; 2001; 12(12):17-8. PubMed ID: 11570085
[No Abstract] [Full Text] [Related]
9. Garlic reduces saquinavir blood levels 50%; may affect other drugs.
James JS
AIDS Treat News; 2001 Dec; (375):2-3. PubMed ID: 11810949
[No Abstract] [Full Text] [Related]
10. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
[No Abstract] [Full Text] [Related]
11. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.
Inugala S; Eedara BB; Sunkavalli S; Dhurke R; Kandadi P; Jukanti R; Bandari S
Eur J Pharm Sci; 2015 Jul; 74():1-10. PubMed ID: 25845633
[TBL] [Abstract][Full Text] [Related]
12. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Marzolini C; Gibbons S; Khoo S; Back D
J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
[TBL] [Abstract][Full Text] [Related]
13. Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.
Daskapan A; Tran QTD; Cattaneo D; Gervasoni C; Resnati C; Stienstra Y; Bierman WFW; Kosterink JGW; van der Werf TS; Proost JH; Alffenaar JC; Touw DJ
Ther Drug Monit; 2019 Feb; 41(1):59-65. PubMed ID: 30489547
[TBL] [Abstract][Full Text] [Related]
14. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
McCoy C
Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
[TBL] [Abstract][Full Text] [Related]
15. Darunavir: pharmacokinetics and drug interactions.
Back D; Sekar V; Hoetelmans RM
Antivir Ther; 2008; 13(1):1-13. PubMed ID: 18389894
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
[TBL] [Abstract][Full Text] [Related]
17. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
Curran A; Pérez-Valero I; Moltó J
AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Metsu D; Toutain PL; Chatelut E; Delobel P; Gandia P
J Antimicrob Chemother; 2017 Sep; 72(9):2407-2409. PubMed ID: 28595364
[TBL] [Abstract][Full Text] [Related]
19. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
